Nov 29, 2021 / 05:00PM GMT
Jacob Johnson - Stephens Inc. - Analyst
Good morning, everybody. Welcome to day one of the Stephens Investment Conference. I'm Jacob Johnson, life science tools and diagnostics analyst here at Stephens. Really delighted to be joined by the team from MaxCyte. We've got CEO, Doug Doerfler today with us; along with Sean Menarguez from Investor Relations.
(Conference Instructions) And with that out of the way, Doug, I'll turn it over to you for some opening comments, and then we'll launch into Q&A.
Doug Doerfler - MaxCyte, Inc. - President & CEO
Well, thanks, Jacob. It is really a pleasure to be here, our first Stephens Conference and obviously virtual. And thank you for you and your team's support during this incredible process as a public company. So thanks, Jacob. Looking forward to today's discussion. Thank you.
Questions and Answers:
Jacob Johnson - Stephens Inc. - AnalystShort and sweet. I like it, Doug. So maybe to kick things off, for those who may be less familiar with MaxCyte and the